Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 May 3. doi: 10.1158/1078-0432.CCR-18-4142. [Epub ahead of print]

PMID:
31053602
2.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

3.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Mar 1. doi: 10.1158/1078-0432.CCR-18-1538. [Epub ahead of print] Review.

PMID:
30824587
4.

Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.

Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL.

Clin Cancer Res. 2019 May 15;25(10):3054-3062. doi: 10.1158/1078-0432.CCR-18-2599. Epub 2019 Feb 22.

PMID:
30796036
5.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.

PMID:
30742120
6.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.

Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL.

NPJ Breast Cancer. 2018 Dec 10;4:40. doi: 10.1038/s41523-018-0095-1. eCollection 2018.

7.

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.

Pelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL.

Breast Cancer Res. 2018 Dec 17;20(1):154. doi: 10.1186/s13058-018-1076-x.

8.

Immunodivergence in Metastatic Colorectal Cancer.

de Andrea CE, Schalper KA, Sanmamed MF, Melero I.

Cancer Cell. 2018 Dec 10;34(6):876-878. doi: 10.1016/j.ccell.2018.11.012.

PMID:
30537510
9.

Oncolytic virus immunotherapy: future prospects for oncology.

Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS.

J Immunother Cancer. 2018 Dec 4;6(1):140. doi: 10.1186/s40425-018-0458-z. Review.

10.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM.

Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.

11.

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.

Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.

Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. doi: 10.1158/1078-0432.CCR-18-2013. Epub 2018 Sep 10.

PMID:
30201760
12.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

13.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.

14.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA.

Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.

15.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL.

J Immunother Cancer. 2017 Oct 17;5(1):81. doi: 10.1186/s40425-017-0285-7.

16.

Interleukin-8 in cancer pathogenesis, treatment and follow-up.

Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I.

Cancer Treat Rev. 2017 Nov;60:24-31. doi: 10.1016/j.ctrv.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28866366
17.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

18.

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.

19.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.

Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL.

Gynecol Oncol. 2017 Apr;145(1):154-158. doi: 10.1016/j.ygyno.2017.02.002. Epub 2017 Feb 11.

20.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

21.

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL.

Mod Pathol. 2017 Mar;30(3):340-349. doi: 10.1038/modpathol.2016.186. Epub 2016 Nov 11.

22.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL.

J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.

23.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I.

Cancer Res. 2016 Oct 15;76(20):5994-6005. Epub 2016 Aug 22.

24.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.

Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL.

Breast Cancer Res. 2016 Jul 29;18(1):78. doi: 10.1186/s13058-016-0737-x.

25.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.

26.

Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement.

Zarrella ER, Coulter M, Welsh AW, Carvajal DE, Schalper KA, Harigopal M, Rimm DL, Neumeister VM.

Lab Invest. 2016 Sep;96(9):1016-25. doi: 10.1038/labinvest.2016.73. Epub 2016 Jun 27.

27.

Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

Datar I, Schalper KA.

Clin Cancer Res. 2016 Jul 15;22(14):3422-4. doi: 10.1158/1078-0432.CCR-16-0336. Epub 2016 Apr 13.

28.

Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.

Schalper KA, Kaftan E, Herbst RS.

Clin Cancer Res. 2016 May 1;22(9):2102-4. doi: 10.1158/1078-0432.CCR-16-0169. Epub 2016 Mar 8.

29.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL.

JAMA Oncol. 2016 Jan;2(1):46-54. doi: 10.1001/jamaoncol.2015.3638. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

30.

Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19.

Barrera F, Azócar L, Molina H, Schalper KA, Ocares M, Liberona J, Villarroel L, Pimentel F, Pérez-Ayuso RM, Nervi F, Groen AK, Miquel JF.

Ann Hepatol. 2015 Sep-Oct;14(5):710-21.

31.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Sanmamed MF, Rodriguez I, Schalper KA, Oñate C, Azpilikueta A, Rodriguez-Ruiz ME, Morales-Kastresana A, Labiano S, Pérez-Gracia JL, Martín-Algarra S, Alfaro C, Mazzolini G, Sarno F, Hidalgo M, Korman AJ, Jure-Kunkel M, Melero I.

Cancer Res. 2015 Sep 1;75(17):3466-78. doi: 10.1158/0008-5472.CAN-14-3510. Epub 2015 Jun 25.

32.

Spironolactone inhibits the activity of the Na+/H+ exchanger in the aorta of mineralocorticoid-induced hypertensive rats.

Carreño JE, Verdugo FJ, Contreras F, Montellano FA, Veloso S, Schalper KA, Sandoval M, Villanueva S, Marusic E, Irarrazabal CE.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1225-31. doi: 10.1177/1470320315587193. Epub 2015 May 21.

PMID:
25997821
33.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

34.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju435. doi: 10.1093/jnci/dju435. Print 2015 Mar.

35.

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL.

Lab Invest. 2015 Apr;95(4):385-96. doi: 10.1038/labinvest.2014.157. Epub 2014 Dec 15. Review.

36.
37.

Possible role of hemichannels in cancer.

Schalper KA, Carvajal-Hausdorf D, Oyarzo MP.

Front Physiol. 2014 Jun 27;5:237. doi: 10.3389/fphys.2014.00237. eCollection 2014.

38.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.

Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.

39.

Role of gap junctions and hemichannels in parasitic infections.

Vega JL, Subiabre M, Figueroa F, Schalper KA, Osorio L, González J, Sáez JC.

Biomed Res Int. 2013;2013:589130. doi: 10.1155/2013/589130. Epub 2013 Oct 23. Review.

40.

Programmed death ligand-1 expression in non-small cell lung cancer.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL.

Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.

41.
42.

Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Viray H, Bradley WR, Schalper KA, Rimm DL, Gould Rothberg BE.

Arch Pathol Lab Med. 2013 Aug;137(8):1063-73. doi: 10.5858/arpa.2012-0284-OA.

43.

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).

Velcheti V, Rimm DL, Schalper KA.

J Thorac Oncol. 2013 Jun;8(6):803-5. doi: 10.1097/JTO.0b013e318292be18.

44.

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.

Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET.

Oncogene. 2014 Mar 13;33(11):1438-47. doi: 10.1038/onc.2013.78. Epub 2013 Apr 1.

45.

Regulation of intercellular calcium signaling through calcium interactions with connexin-based channels.

Orellana JA, Sánchez HA, Schalper KA, Figueroa V, Sáez JC.

Adv Exp Med Biol. 2012;740:777-94. doi: 10.1007/978-94-007-2888-2_34. Review.

PMID:
22453969
46.

p16ink4a expression in benign and malignant melanocytic conjunctival lesions.

Zoroquiain P, Fernandes BF, González S, Novais GN, Schalper KA, Burnier MN Jr.

Int J Surg Pathol. 2012 Jun;20(3):240-5. doi: 10.1177/1066896911435697. Epub 2012 Jan 26.

PMID:
22287653
47.

Modulation of gap junction channels and hemichannels by growth factors.

Schalper KA, Riquelme MA, Brañes MC, Martínez AD, Vega JL, Berthoud VM, Bennett MV, Sáez JC.

Mol Biosyst. 2012 Mar;8(3):685-98. doi: 10.1039/c1mb05294b. Epub 2012 Jan 4. Review.

PMID:
22218428
48.

[Primary cerebral lymphomatoid granulomatosis in a HIV-positive patient. Case report].

Schalper KA, Valbuena JR.

Rev Med Chil. 2011 Feb;139(2):218-23. doi: /S0034-98872011000200012. Epub 2011 Jul 11. Spanish.

49.

Cation permeation through connexin 43 hemichannels is cooperative, competitive and saturable with parameters depending on the permeant species.

Orellana JA, Díaz E, Schalper KA, Vargas AA, Bennett MV, Sáez JC.

Biochem Biophys Res Commun. 2011 Jun 17;409(4):603-9. doi: 10.1016/j.bbrc.2011.05.031. Epub 2011 May 12.

50.

Connexin 43 hemichannels mediate the Ca2+ influx induced by extracellular alkalinization.

Schalper KA, Sánchez HA, Lee SC, Altenberg GA, Nathanson MH, Sáez JC.

Am J Physiol Cell Physiol. 2010 Dec;299(6):C1504-15. doi: 10.1152/ajpcell.00015.2010. Epub 2010 Sep 29.

Supplemental Content

Loading ...
Support Center